From a technical standpoint, Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is showing signs of a base breakout.
As highlighted in the chart (August 22, 2025), the stock has established support at the 0.618 Fibonacci retracement from the summer 2023 lows.
Volume has been steadily increasing as higher lows form, a classic signal of accumulation.
Current Setup
The stock has carved out a multi-month base after correcting sharply from its 2024 highs above CA$1.30. Support was found almost perfectly at the 0.618 Fibonacci retracement of the 2023–2024 advance, which coincides with a clear volume pickup as higher lows were established. That type of confluence, Fibonacci retracement, volume confirmation, and higher lows, is often the foundation of a sustainable trend reversal.
Momentum is also supportive. RSI has broken out of a long consolidation band, and MACD has turned positive, suggesting early upside momentum is being recognized by the market.
Targets
- First Target: CA$0.65
This aligns with the first resistance shelf from spring 2025. A close above this level would confirm a breakout from the recent consolidation and trigger broader technical buying interest. - Second Target: CA$1.05
The next logical resistance is the early-2024 congestion zone, where the stock repeatedly stalled on prior rallies. Reclaiming this zone would mark a return to mid-cycle valuation levels and confirm a higher-timeframe reversal. - Third Target: CA$1.25
This coincides with the last major swing high before the breakdown. Surpassing this level would re-establish a longer-term uptrend and likely attract both technical traders and momentum-driven funds.
The Big Picture Target is CA$1.75.
Should the stock sustain a breakout through CA$1.25 with strong volume, the chart implies an eventual move toward CA$1.75, a level consistent with measured-move projections from the base structure. This would effectively complete a full recovery of the prior cycle's dep correction.
Risk/Support Levels
Immediate support is anchored around CA$0.45–CA$0.50, where the most recent pullback lows and the 50-day moving average converge.
A breakdown below CA$0.38 (the 2025 low) would invalidate the bullish reversal setup and shift bias back to defensive.
Finally
The stock is transitioning from a prolonged consolidation into a confirmed reversal phase. Volume patterns, Fibonacci retracement support, and momentum indicators all argue for the likelihood of higher targets being reached in sequence.
The Point of Recognition (POR) appears to have formed, suggesting institutional and retail buyers are beginning to re-enter.
Conclusion
For speculative investors, the stock offers a technical setup with clearly defined upside targets.
We view Rocket Doctor AI at current levels of CA$ 0.60 and US$ 0.45 as a Speculative Buy.
Visit Rocket Doctor AI's website Here
| Want to be the first to know about interesting Life Sciences Tools & Diagnostics investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
-
For this article, the Company has paid Street Smart, an affiliate of Streetwise Reports, between US$2,000.
- As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI.
- Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
- Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company.
For additional disclosures, please click here.
John Newell Disclaimer
As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.
